Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4183 Establishment of novel patient-derived preclinical models for neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) arise in different organs and are heterogeneous with limited treatment options. Preclinical models established from patient tumor specimens enable precision oncology by assessing the response to various drug treatments.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Li B, Li Y, Tsui H,

Keywords: preclinical models, patient-derived organoids, patient-derived xenografts, drug screening,

#4047 The role of adipocytes in neuroendocrine neoplasms: Molecular and metabolic adaptations

Introduction: It is recognized that the adipose tissue plays a major role in cancer. Recent evidence suggests the existence of altered metabolic pathways in neuroendocrine neoplasms (NENs), influencing tumor development and evolution, and thereby clinical outcomes.

Conference:

Presenting Author: Calabrese C

Authors: Calabrese C, Dellavalle S, Miserocchi G, Gabellone S, Spadazzi C,

Keywords: neuroendocrine neoplasm, adipocytes, metabolism, RNA-seq, 3D co-cultures,

#3966 PTK2 PROTAC unveiled as a selective inhibitor of gastrointestinal neuroendocrine cell proliferation via multi-target drug screening

Introduction: Gastrointestinal neuroendocrine tumors (GI-NETs) exhibit a complex and diverse nature, posing challenges in their effective treatment and management. While there have been advancements in treatment options, addressing the need for more effective and targeted therapies remains a significant issue, especially for patients with advanced or metastatic disease. Improving outcomes in the management of patients with GI-NETs is a key priority, and further research and development are crucial in this regard.

Conference:

Presenting Author: Gagliano T

Authors: Malavasi E, Toffoli L, Dainotto M, Gagliano T,

Keywords: Protac, PTK2, Screening, GI-NETs,

#3758 A novel hormone-based anti-SSTR T-cell engager for the treatment of neuroendocrine tumors

Introduction: Somatostatin receptors (SSTRs) are overexpressed by well-differentiated neuroendocrine tumors (NETs).

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Medina E, Mason C, Snedal S,

Keywords: Bispecific T cell Engagers, CD3, SSTR, TILs, Immunotherapy,